CA9 and neoplasm: In the third group, three patients were treated similarly to the patients in the second group, but with the addition of a strategy to block CAIX recognition in normal tissues: an extra intravenous infusion of 5 mg anti-CAIX cG250 mAb three days before the start of CAR T cell infusions, leaving only CAIX expressed at higher levels in the tumor site available for the CAR T cell action.